HL-398: Five-Year Overall Survival from the CheckMate 205 Study of Nivolumab for Relapsed or Refractory (R/R) Classical Hodgkin Lymphoma (cHL)
Stephen M. Ansell, Paul J. Bröckelmann, Gottfried von Keudell, Hun Ju Lee, Armando Santoro, Pier Luigi Zinzani, Graham P. Collins, Jonathon B. Cohen, Jan Paul de Boer, John Kuruvilla, Kerry J. Savage, Marek Trněný, Mariano Provencio, Ulrich Jaeger, Wolfgang Willenbacher, René Swanink, Margaret A. Shipp, Andreas Engert, Philippe Armand
Topics & Concepts
MedicineInternal medicineNivolumabContext (archaeology)Refractory (planetary science)Brentuximab vedotinProgression-free survivalGastroenterologySurgeryLymphomaOverall survivalImmunotherapyCancerHodgkin lymphomaPhysicsAstrobiologyPaleontologyBiologyLymphoma Diagnosis and TreatmentCancer Immunotherapy and BiomarkersCAR-T cell therapy research